{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:15:06Z","timestamp":1790720106582,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40272-026-00750-9","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:36:34Z","timestamp":1776868594000},"page":"441-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Copper Histidinate: Pediatric First Approval"],"prefix":"10.1007","volume":"28","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"issue":"5","key":"750_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm12051769","volume":"12","author":"A Rozensztrauch","year":"2023","unstructured":"Rozensztrauch A, Dzien I, \u015amigiel R. Health-related quality of life and family functioning of primary caregivers of children with Menkes disease. J Clin Med. 2023;12(5):1\u201314.","journal-title":"J Clin Med"},{"key":"750_CR2","unstructured":"U.S. Food & Drug Administration. Orphan Drug Designations and approvals: copper histidinate for treatment of Menkes disease. 2012. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=366312. Accessed 23 Mar 2026."},{"key":"750_CR3","unstructured":"Fortress Biotech. Fortress Biotech announces Cyprium Therapeutics CUTX-101 (copper histidinate) granted FDA Fast Track Designation for treatment of classic Menkes disease [media release]. 2 Jul 2018. http:\/\/www.fortressbiotech.com."},{"key":"750_CR4","unstructured":"Fortress Biotech. Fortress Biotech reports record fourth quarter and full-year 2019 financial results and recent corporate highlights [media release]. 16 Mar 2020. http:\/\/www.fortressbiotech.com."},{"key":"750_CR5","unstructured":"Fortress Biotech. Fortress Biotech announces Breakthrough Therapy Designation for CUTX-101, copper histidinate, for the treatment of Menkes disease [media release]. 15 Dec 2020. http:\/\/www.fortressbiotech.com."},{"key":"750_CR6","unstructured":"U.S. Food & Drug Administration. FDA approves first treatment for children with Menkes disease [media release]. 12 Jan 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-children-menkes-disease."},{"key":"750_CR7","unstructured":"Cyprium Therapeutics Inc. Fortress Biotech and Cyprium Therapeutics announce U.S. FDA approval of ZYCUBO\u00ae (copper histidinate), the first and only approved treatment for Menkes disease in the United States [media release]. 13 Jan 2026. https:\/\/www.cypriumtx.com\/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda-approval-of-zycubo-copper-histidinate-the-first-and-only-approved-treatment-for-menkes-disease-in-the-united-states\/."},{"key":"750_CR8","unstructured":"Fortress Biotech. Fortress Biotech announces Positive Opinion on Orphan Drug Designation received from the European Medicines Agency for CUTX-101, copper histidinate, for the treatment of Menkes disease [media release]. 31 Jul 2020. http:\/\/www.fortressbiotech.com."},{"key":"750_CR9","unstructured":"Zydus Lifesciences Ltd and Sentynl Therapeutics Inc. ZYCUBO\u00ae (copper histidinate) for injection, for subcutaneous use: US prescribing information. 2026. https:\/\/sentynl.com\/wp-content\/uploads\/2026\/01\/ZYCUBO_USPI_and_IFU_01-12-2026.pdf. Accessed 23 Mar 2026."},{"issue":"1","key":"750_CR10","first-page":"252","volume":"149","author":"SG Kaler","year":"2022","unstructured":"Kaler SG, Munim S, Chen M, et al. Copper histidinate treatment for Menkes disease (kinky hair syndrome) [abstract plus poster]. Pediatrics. 2022;149(1):252.","journal-title":"Pediatrics"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00750-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-026-00750-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-026-00750-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:10:57Z","timestamp":1784290257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-026-00750-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["750"],"URL":"https:\/\/doi.org\/10.1007\/s40272-026-00750-9","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}